RHYTHM PHARMACEUTICALS INC
NASDAQ: RYTM (Rhythm Pharmaceuticals, Inc.)
Kemas kini terakhir: 3 jam lalu108.36
2.41 (2.27%)
| Penutupan Terdahulu | 105.95 |
| Buka | 105.52 |
| Jumlah Dagangan | 532,997 |
| Purata Dagangan (3B) | 775,796 |
| Modal Pasaran | 7,231,519,232 |
| Harga / Jualan (P/S) | 37.11 |
| Harga / Buku (P/B) | 45.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -123.28% |
| Margin Operasi (TTM) | -143.73% |
| EPS Cair (TTM) | -2.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 69.65% |
| Nisbah Semasa (MRQ) | 3.30 |
| Aliran Tunai Operasi (OCF TTM) | -113.49 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.71 M |
| Pulangan Atas Aset (ROA TTM) | -51.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Rhythm Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | 0.38 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 103.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Primecap Management Co/Ca/ | 30 Sep 2025 | 4,262,859 |
| Nea Management Company, Llc | 30 Sep 2025 | 2,909,956 |
| Perceptive Advisors Llc | 30 Sep 2025 | 2,438,969 |
| Driehaus Capital Management Llc | 30 Sep 2025 | 1,383,775 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 1,244,932 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 167.00 (Citizens, 54.12%) | Beli |
| Median | 143.00 (31.97%) | |
| Rendah | 125.00 (HC Wainwright & Co., 15.36%) | Beli |
| Purata | 144.88 (33.70%) | |
| Jumlah | 8 Beli | |
| Harga Purata @ Panggilan | 108.44 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Jan 2026 | 125.00 (15.36%) | Beli | 102.59 |
| 22 Dec 2025 | 123.00 (13.51%) | Beli | 112.88 | |
| Wells Fargo | 20 Jan 2026 | 145.00 (33.81%) | Beli | 102.59 |
| Needham | 09 Jan 2026 | 148.00 (36.58%) | Beli | 101.02 |
| 11 Dec 2025 | 145.00 (33.81%) | Beli | 117.62 | |
| Guggenheim | 17 Dec 2025 | 140.00 (29.20%) | Beli | 111.86 |
| Canaccord Genuity | 12 Dec 2025 | 141.00 (30.12%) | Beli | 113.56 |
| 10 Nov 2025 | 114.00 (5.20%) | Beli | 97.63 | |
| Citizens | 12 Dec 2025 | 167.00 (54.12%) | Beli | 113.56 |
| Goldman Sachs | 12 Dec 2025 | 157.00 (44.89%) | Beli | 113.56 |
| Citigroup | 25 Nov 2025 | 136.00 (25.51%) | Beli | 108.75 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |